J 2021

Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients

PEHALOVÁ, Lucie, Denisa KREJČÍ, Jana HALÁMKOVÁ, Lenka ŠMARDOVÁ, Lenka ŠNAJDROVÁ et. al.

Basic information

Original name

Significant current epidemiological trend: Haematological malignancies as subsequent primary tumours in cancer patients

Authors

PEHALOVÁ, Lucie (203 Czech Republic, guarantor, belonging to the institution), Denisa KREJČÍ (203 Czech Republic, belonging to the institution), Jana HALÁMKOVÁ (203 Czech Republic, belonging to the institution), Lenka ŠMARDOVÁ (203 Czech Republic, belonging to the institution), Lenka ŠNAJDROVÁ (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, belonging to the institution)

Edition

Cancer Epidemiology, Oxford, Elsevier, 2021, 1877-7821

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 2.890

RIV identification code

RIV/00216224:14110/21:00121472

Organization unit

Faculty of Medicine

UT WoS

000652749700004

Keywords in English

Haematological malignancies; Subsequent primary tumour; Time trends; Standardised incidence ratio; Survival

Tags

International impact, Reviewed
Změněno: 15/6/2021 13:17, Mgr. Tereza Miškechová

Abstract

V originále

Background Numbers of patients who develop subsequent primary tumours have markedly increased recently. This study aimed to carry out a comprehensive analysis documenting the risk of incidence of subsequent haematological malignancies. Methods The Czech National Cancer Registry was the main data source, containing records of 126,822 haematological malignancies diagnosed in the period 1977–2016. Subsequent haematological malignancies were identified according to IACR rules. Joinpoint regression was employed to assess the time trends. The risk of development of subsequent haematological malignancy was evaluated by the standardised incidence ratio. The Kaplan–Meier curves were used to assess the differences in survival. Results Age-standardised incidence of subsequent haematological malignancies increased from 0.5 in 1977 to 9.1 in 2016. In 1992, there was a significant change in the trend: a sharp increase by 7.7 % annually was revealed thereafter. The risk of development of a haematological malignancy was approximately 1.5 times higher in persons with history of any cancer than in the general Czech population. Patients with haematological malignancies – mainly myelodysplastic syndromes, polycythaemia vera and non-Hodgkin lymphoma – were shown to be at the highest risk of developing a subsequent haematological malignancy. While the median survival following a first haematological malignancy was 2.3 years, it was only 1.1 years for subsequent haematological malignancies (p < 0.001). Conclusions Our study identified the highest-risk diagnoses in terms of development of subsequent haematological malignancy. The results might be useful to set up correctly follow-up procedures from which cancer patients could benefit.